LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).

被引：0
作者：
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Rambam Hlth Care Campus, Haifa, Israel
[3] Huntsman Canc Inst, Salt Lake City, UT USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Merck & Co Inc, Rahway, NJ USA
[6] Westmead Hosp, Sydney, NSW, Australia
[7] Macquarie Univ, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4603
引用
收藏
页数：1
相关论文
共 50 条
  • [11] LITESPARK-022: A phase 3 study of pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)
    Choueiri, Toni K.
    Bedke, Jens
    Karam, Jose A.
    Mckay, Rana R.
    Motzer, Robert J.
    Pal, Sumanta K.
    Suarez, Cristina
    Uzzo, Robert
    Liu, Hong
    Burgents, Joseph E.
    Sharma, Manish
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Bauer, Todd Michael
    Merchan, Jaime R.
    Mcdermott, David F.
    Figlin, Robert A.
    Arrowsmith, Edward
    Michaelson, M. Dror
    Heath, Elisabeth I.
    D'Souza, Anishka
    Zhao, Song
    Kassalow, Laurent
    Perini, Rodolfo F.
    Vickery, Donna
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 549 - 549
  • [13] Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study
    Atkins, Michael B.
    Ghatalia, Pooja
    Merchan, Jaime R.
    George, Saby
    Haanen, John
    Gurney, Howard
    Ravilla, Rahul
    Van Der Veldt, Astrid Aplonia Maria
    Beuselinck, Benoit
    Pokataev, Ilya
    Suelmann, Britt
    Tuthill, Mark H.
    Vaena, Daniel A.
    Zagouri, Flora
    Lin, Jianxin
    Perini, Rodolfo F.
    Liu, Yanfang
    Brugarolas, James
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [14] Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study
    Albiges, Laurence
    Choueiri, Toni K.
    Peltola, Katriina
    de Velasco, Guillermo
    Burotto, Mauricio
    Suarez, Cristina
    Ghatalia, Pooja
    Iacovelli, Roberto
    Lam, Elaine T.
    Verzoni, Elena
    Gumus, Mahmut
    Stadler, Walter M.
    Kollmannsberger, Christian
    Melichar, Bohuslav
    Venugopal, Balaji
    Xing, Aiwen
    Perini, Rodolfo F.
    Vickery, Donna
    Rini, Brian
    Powles, Thomas
    ONCOLOGIST, 2024, 29 : S3 - S4
  • [15] Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
    Powles, Thomas
    Albiges, Laurence
    Jalkanen, Katriina Johanna
    De Velasco, Guillermo
    Burotto, Mauricio
    Ghatalia, Pooja
    Suarez, Cristina
    Lam, Elaine T.
    Iacovelli, Roberto
    Gumus, Mahmut
    Verzoni, Elena
    Kollmannsberger, Christian K.
    Stadler, Walter Michael
    Venugopal, Balaji
    Shinde, Reshma
    Saretsky, Todd L.
    He, Li
    Vickery, Donna
    Choueiri, Toni K.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 361 - 361
  • [16] Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
    Albiges, L.
    Rini, B. I.
    Peltola, K.
    Oria, G. A. De Velasco
    Burotto, M.
    Rodriguez, C. Suarez
    Ghatalia, P.
    Iacovelli, R.
    Lam, E. T.
    Verzoni, E.
    Gumus, M.
    Stadler, W. M.
    Kollmannsberger, C. K.
    Melichar, B.
    Venugopal, B.
    Wang, A.
    Perini, R.
    Vickery, D.
    Powles, T. B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1329 - S1330
  • [17] Randomized, double-blind phase III study in treatment and Pazopanib in treatment with a cytokine in patients with advanced renal cell carcinoma (RCC)
    Geissler, K.
    Dittrich, C.
    Marberger, M.
    Greil, R.
    Jeglitsch, M.
    Chen, M.
    Sternberg, C.
    ONKOLOGIE, 2010, 33 : 92 - 92
  • [18] A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC).
    Famoyin, C
    Byrnes, C
    Roberts, S
    Gollob, J
    Atkins, M
    Mier, J
    Ko, YJ
    Gautam, S
    McDemott, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 443S - 443S
  • [19] Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
    Choueiri, Toni K.
    Merchan, Jaime R.
    Figlin, Robert
    Mcdermott, David F.
    Arrowsmith, Edward
    Michaelson, M. Dror
    Tykodi, Scott S.
    Heath, Elisabeth, I
    Spigel, David R.
    D'Souza, Anishka
    Kassalow, Laurent
    Perini, Rodolfo F.
    Vickery, Donna
    Bauer, Todd M.
    LANCET ONCOLOGY, 2025, 26 (01) : 64 - 73
  • [20] Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
    Rini, B. I.
    Rodriguez, C. Suarez
    Albiges, L.
    Jalkanen, K.
    Oria, G. A. De Velasco
    Burotto, M.
    Ghatalia, P.
    Iacovelli, R.
    Lam, E. T.
    Verzoni, E.
    Gumus, M.
    Stadler, W.
    Kollmannsberger, C. K.
    Melichar, B.
    Venugopal, B.
    Lin, J.
    Perini, R.
    Vickery, D.
    Choueiri, T. K.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : 1262 - 1263
12345